Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)
Leeds Assessment of Neuropathic Symptoms and Signs · Also known as: LANSS Pain Scale, Leeds Neuropathic Symptoms
The LANSS is a brief seven-item hybrid screening and diagnostic tool designed to differentiate neuropathic pain from non-neuropathic (nociceptive) pain. Developed by Mark Bennett at the University of Leeds in 2001, it combines five patient-reported symptom items with two clinician-performed neurological examination findings. With a sensitivity of 82% and specificity of 80%, LANSS is among the most accurate tools for identifying whether a patient's pain has a neuropathic component, making it invaluable in clinical practice and research settings where pain etiology classification is essential.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
LANSS is ideal as a first-line screening tool in primary care and specialty clinics for patients presenting with chronic pain, to rapidly differentiate neuropathic from non-neuropathic etiology and guide initial treatment selection. Use in clinical research trials where pain etiology classification is essential for inclusion/exclusion or stratification. Use in observational studies characterizing pain phenotypes in specific diseases. Use in clinical settings with mixed pain etiologies (e.g., cancer patients with both nociceptive tumor pain and chemotherapy-induced neuropathy) to identify neuropathic component. Less suitable for quantifying neuropathic pain severity (use NPSI or other severity measures) or for detailed symptom profiling (use NPSI); LANSS is a screening classification tool, not a severity scale.
Strengths & limitations
- High diagnostic accuracy (82% sensitivity, 80% specificity) for differentiating neuropathic from non-neuropathic pain with simple yes/no threshold
- Brief administration (5 minutes) with no special equipment or training required; highly practical for routine clinic use
- Combines both subjective symptom report and objective examination findings, improving diagnostic confidence beyond symptom report alone
- Applicability across diverse pain etiologies and patient populations; not disease-specific
- Extensive validation in multiple international languages and patient populations; widely recognized as standard screening tool
- Designed as screening/classification tool, not severity measure; does not quantify neuropathic pain intensity or track symptom changes with treatment (use NPSI for severity)
- Sensitivities and specificities of 82%/80% indicate non-negligible false negatives (~18%) and false positives (~20%); clinical judgment is needed for borderline scores
- Examination-based items (skin temperature, color) may be affected by environmental factors or observer technique; require consistent standardized assessment
- Less suitable in patients unable to communicate symptoms clearly (cognitive impairment, language barriers) or those with limited skin accessibility for examination
Frequently asked
If LANSS score is 4, does that mean the patient definitely has non-neuropathic pain?
A LANSS score of 4 (below threshold 5) suggests non-neuropathic pain is more likely, but it does not rule out neuropathic pain. Remember, ~18% of patients with confirmed neuropathic pain score LANSS <5 (false negatives). If clinical suspicion of neuropathic pain is high despite low LANSS, consider additional diagnostic testing (nerve conduction studies, quantitative sensory testing, skin biopsy) or consultation with a neurologist/pain specialist.
Can I use LANSS in patients with skin disease (eczema, psoriasis, severe scarring)?
LANSS examination items require assessment of skin color and sweating, which may be unreliable in patients with significant skin disease. In such cases, document examination limitations and rely primarily on symptom items (first 5 LANSS items). If examination findings cannot be reliably assessed, consider alternative neuropathic pain screening tools (DN4, PainDETECT) that rely more on symptom items, or proceed with clinical judgment and additional diagnostic testing.
Is LANSS score directly correlated with neuropathic pain severity?
No. LANSS is a categorical classification tool (neuropathic ≥5 vs. non-neuropathic <5), not a severity measure. A patient with LANSS 7 does not necessarily have more severe pain than one with LANSS 5. To quantify neuropathic pain severity and track treatment response, use severity-focused instruments like NPSI or numeric rating scales. LANSS is useful for determining whether neuropathic component is present, not for severity quantification.
How does LANSS compare to DN4 or PainDETECT for neuropathic pain screening?
All three are valid neuropathic pain screening tools with comparable diagnostic accuracy (sensitivity/specificity in 75-85% range). LANSS emphasizes examination findings; DN4 and PainDETECT are symptom-focused questionnaires. LANSS is briefest (7 items, 5 minutes); DN4 and PainDETECT are slightly longer. Choice depends on clinical context and examiner preference. LANSS is preferred when clinician wants quick screening with examination; DN4/PainDETECT are preferred for self-report or remote administration.
Sources
- Bennett, M. I. (2001). The LANSS Pain Scale: The Leeds Assessment of Neuropathic Symptoms and Signs. Pain, 92(1-2), 147-157. DOI: 10.1016/S0304-3959(00)00482-6 ↗
How to cite this page
ScholarGate. (2026, June 3). Leeds Assessment of Neuropathic Symptoms and Signs. ScholarGate. https://scholargate.app/en/neurology/leeds-neuropathic-symptoms
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →